Company Description
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases.
The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity.
The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephen Glover |
Contact Details
Address: 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 United States | |
| Phone | (754) 231-1688 |
| Website | zyversa.com |
Stock Details
| Ticker Symbol | ZVSA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859007 |
| CUSIP Number | 98987D201 |
| ISIN Number | US98987D2018 |
| Employer ID | 86-2685744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer and President |
| Peter Wolfe | Chief Financial Officer and Secretary |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs and Chairman of Renal Scientific Advisory Board |
| Karen A. Cashmere | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2025 | EFFECT | Notice of Effectiveness |